about
Challenges to treat hypogonadism in prostate cancer patients: implications for endocrinologists, urologists and radiotherapistsIntegrating psychotherapy and pharmacotherapy in the treatment of premature ejaculationThe psychosexual profile of sexual assistants: an internet-based explorative study.Premature ejaculation results in female sexual distress: standardization and validation of a new diagnostic tool for sexual distress.The sexual attraction toward disabilities: a preliminary internet-based study.Nucleo-cytoplasmic transport as a therapeutic target of cancerOntogenetic profile of the expression of thyroid hormone receptors in rat and human corpora cavernosa of the penisForeign bodies aspirated in children: role of bronchoscopy.MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signalsMeasurement of the thickness of the urethrovaginal space in women with or without vaginal orgasm.Arachidonic acid modulates the crosstalk between prostate carcinoma and bone stromal cells.Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer modelsSquamous cell carcinoma of the rectum: The treatment paradigm.Treatment of Solitary Painful Osseous Metastases with Radiotherapy, Cryoablation or Combined Therapy: Propensity Matching Analysis in 175 Patients.Topical application of platelet supernatant gel in the management of radiotherapy-induced mucositis: a case reportIs testosterone a friend or a foe of the prostate?Advances in imaging and in non-surgical salvage treatments after radiorecurrence in prostate cancer: what does the oncologist, radiotherapist and radiologist need to know?Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer.Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models.Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay.Oral Platelet Gel Supernatant Plus Supportive Medical Treatment Versus Supportive Medical Treatment in the Management of Radiation-induced Oral Mucositis: A Matched Explorative Active Control Trial by Propensity Analysis.Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines.Crocus sativus stigma extract and its major constituent crocin possess significant antiproliferative properties against human prostate cancer.PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells.A feasibility study of percutaneous Radiofrequency Ablation followed by Radiotherapy in the management of painful osteolytic bone metastases.Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.Alexithymia and vaginismus: a preliminary correlation perspective.The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia.Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases.5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro.Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels.Her2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatment.Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.
P50
Q26773738-5780FDC8-3BE5-467B-A122-5E5C1EEC62E5Q26865863-2730C704-1152-4CF9-8921-7358BDBB353CQ33740296-24948C9B-6F8E-4FC9-ABFE-69FD9043138CQ34311029-4F4597D7-A02B-4144-8E41-1769C3CAE713Q34372065-EE9D7CE5-A206-415A-8D59-6D3F50DF1CB7Q34452108-1ECCD07E-97AB-4656-B99E-53E0FFA5E973Q34474852-48839E79-34ED-4369-B7C6-81414DF77C5EQ34579996-B70ED02F-F2D5-46D1-B0E3-56F14FF567FBQ34721752-55380F6B-19EB-4D92-8D4B-A56086A231BDQ34741840-76292E3C-0D34-457A-8ECE-544D5D6DAF64Q34756844-05B4DACF-9373-4760-949C-57D41BD32092Q35590793-45346705-00AC-4867-8F24-D3A8E0A08B32Q35625617-57042431-A389-43C6-AAE4-0EB9B2E59E87Q35672049-4AC4AA1E-7E62-44CE-9250-2B95C7F735C7Q37588908-7F87732E-6C56-41B0-9781-0F78425AACE7Q37860408-39427DA9-E5E6-4A41-81D4-EFC838C035C3Q38026501-4E955729-B870-407F-8C1B-5EC845DE6838Q38223782-709ACC67-2CFA-4E74-85F6-B3EA22DC8DFCQ38848501-AE7ABE1F-38B4-4DA5-ABE4-7FE1B02FA842Q38950408-EE1D1514-CED9-44A0-B436-44CE43869ACAQ39006052-2B0EC0CB-55C8-4D19-AE52-F94CFFC45413Q39010806-AF3ECF96-0235-49CD-8006-8F5F410CB0B8Q39054606-6B247FE1-52D8-480C-AA1E-57ABC69A3730Q39067088-7F8379ED-4B80-4946-B986-DFC9A5362DA4Q39116476-CEB2EAA8-5B8E-455D-A1E0-3D9B5A5D89B3Q39178894-4D34A9C5-8C5E-4B35-B2AB-83638598D641Q39205434-FF238ECB-E54C-47AB-9493-A1F4DD0B9217Q39223480-EF598C72-2857-4364-8A19-2E62ACB6F022Q39266773-5D857529-882E-4251-BF1A-01ED929F9C19Q39434331-2CAD21F6-5EDC-4220-97B2-7B0488D281B7Q39456114-39C00C0C-479E-43B9-A20B-3EA1128A6EABQ39546457-361E681E-751E-4F8A-A039-94240874AEC2Q39568883-79746A11-6D3E-477B-96E4-384A8ADD97A8Q39674898-50322E85-10B6-41D1-B925-68DCFB0E1901Q39706283-AFA51BA9-DCFA-4205-B49F-E49B644C8112Q39723634-15105AC2-7EF8-45AE-BC1B-9E7DBBF7EC86Q39831722-9E6333FD-F0E0-44B0-A6BB-211CC4CC0806Q39873082-3A7E25B8-9884-4115-9E7B-7158CA437597Q39915300-592364D6-E52D-4FD3-BE67-3AADF2D7F4E0Q39999306-E7958D0D-941C-4C94-BC28-32D290619F36
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giovanni Luca Gravina
@ast
Giovanni Luca Gravina
@en
Giovanni Luca Gravina
@es
Giovanni Luca Gravina
@nl
Giovanni Luca Gravina
@sl
type
label
Giovanni Luca Gravina
@ast
Giovanni Luca Gravina
@en
Giovanni Luca Gravina
@es
Giovanni Luca Gravina
@nl
Giovanni Luca Gravina
@sl
prefLabel
Giovanni Luca Gravina
@ast
Giovanni Luca Gravina
@en
Giovanni Luca Gravina
@es
Giovanni Luca Gravina
@nl
Giovanni Luca Gravina
@sl
P106
P1153
6602185835
P21
P31
P496
0000-0002-6797-8324